<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="11115"><DrugName>IMM-201</DrugName><DrugSynonyms><Name><Value>SRL-172</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IPS-21+SRL-172, SR Pharma/YM Bioscience</Value></Name><Name><Value>IMM-201</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>SRP-299, Immodulon</Value></Name><Name><Value>M. vaccae NCTC11659 (tuberculosis/post-traumatic stress disorder), Immodulon Therapeutics</Value></Name></DrugSynonyms><CompanyOriginator id="22356">Silence Therapeutics plc</CompanyOriginator><CompaniesPrimary><Company id="1051823">Immodulon Therapeutics Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="22356">Silence Therapeutics plc</Company><Company id="24845">YM BioSciences Inc</Company><Company id="25528">Onyvax Ltd</Company><Company id="27801">Sakai Chemical Industry Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="11115" type="Drug"><TargetEntity id="263142" type="siDrug">SRL-172</TargetEntity></SourceEntity><SourceEntity id="1051823" type="Company"><TargetEntity id="5021727312" type="organizationId">Immodulon Therapeutics Ltd</TargetEntity></SourceEntity><SourceEntity id="22356" type="Company"><TargetEntity id="4295895614" type="organizationId">Silence Therapeutics PLC</TargetEntity></SourceEntity><SourceEntity id="24845" type="Company"><TargetEntity id="4295861723" type="organizationId">Ym Biosciences Inc</TargetEntity></SourceEntity><SourceEntity id="25528" type="Company"><TargetEntity id="4295985093" type="organizationId">Onyvax Ltd</TargetEntity></SourceEntity><SourceEntity id="27801" type="Company"><TargetEntity id="4295877906" type="organizationId">Sakai Chemical Industry Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1107" type="ciIndication"><TargetEntity id="10039085" type="MEDDRA"></TargetEntity><TargetEntity id="-600684678" type="omicsDisease"></TargetEntity><TargetEntity id="298" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="12" type="ciIndication"><TargetEntity id="10001708" type="MEDDRA"></TargetEntity><TargetEntity id="1180" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"></TargetEntity><TargetEntity id="D019694" type="MeSH"></TargetEntity><TargetEntity id="-1284790527" type="omicsDisease"></TargetEntity><TargetEntity id="429" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1935" type="ciIndication"><TargetEntity id="F43.1" type="ICD10"></TargetEntity><TargetEntity id="10036316" type="MEDDRA"></TargetEntity><TargetEntity id="D013313" type="MeSH"></TargetEntity><TargetEntity id="-1731993138" type="omicsDisease"></TargetEntity><TargetEntity id="38" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="205" type="ciIndication"><TargetEntity id="C43" type="ICD10"></TargetEntity><TargetEntity id="10025650" type="MEDDRA"></TargetEntity><TargetEntity id="D008545" type="MeSH"></TargetEntity><TargetEntity id="-361092282" type="omicsDisease"></TargetEntity><TargetEntity id="705" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="218" type="ciIndication"><TargetEntity id="10062207" type="MEDDRA"></TargetEntity><TargetEntity id="D009164" type="MeSH"></TargetEntity><TargetEntity id="-1047799479" type="omicsDisease"></TargetEntity><TargetEntity id="840" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="221" type="ciIndication"><TargetEntity id="A15" type="ICD10"></TargetEntity><TargetEntity id="10044755" type="MEDDRA"></TargetEntity><TargetEntity id="D014376" type="MeSH"></TargetEntity><TargetEntity id="3389" type="ORPHANET"></TargetEntity><TargetEntity id="-1043612885" type="omicsDisease"></TargetEntity><TargetEntity id="843" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="230" type="ciIndication"><TargetEntity id="10028980" type="MEDDRA"></TargetEntity><TargetEntity id="D009369" type="MeSH"></TargetEntity><TargetEntity id="1855" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="42" type="ciIndication"><TargetEntity id="10005056" type="MEDDRA"></TargetEntity><TargetEntity id="D001749" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="4250" type="ciIndication"><TargetEntity id="10050513" type="MEDDRA"></TargetEntity><TargetEntity id="3229" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="427" type="ciIndication"><TargetEntity id="C53" type="ICD10"></TargetEntity><TargetEntity id="10008342" type="MEDDRA"></TargetEntity><TargetEntity id="D002583" type="MeSH"></TargetEntity><TargetEntity id="-837567682" type="omicsDisease"></TargetEntity><TargetEntity id="590" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="54" type="ciIndication"><TargetEntity id="D002277" type="MeSH"></TargetEntity><TargetEntity id="-233893258" type="omicsDisease"></TargetEntity><TargetEntity id="665" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="755" type="ciIndication"><TargetEntity id="C34" type="ICD10"></TargetEntity><TargetEntity id="10062042" type="MEDDRA"></TargetEntity><TargetEntity id="D008175" type="MeSH"></TargetEntity><TargetEntity id="-243902424" type="omicsDisease"></TargetEntity><TargetEntity id="611" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="94" type="ciIndication"><TargetEntity id="10012431" type="MEDDRA"></TargetEntity><TargetEntity id="D003872" type="MeSH"></TargetEntity><TargetEntity id="-1145429648" type="omicsDisease"></TargetEntity><TargetEntity id="455" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1935">Post traumatic stress disorder</Indication><Indication id="221">Mycobacterium tuberculosis infection</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1107">Allergic rhinitis</Indication><Indication id="12">Allergy</Indication><Indication id="152">Hepatitis B virus infection</Indication><Indication id="205">Melanoma</Indication><Indication id="218">Mycobacterium infection</Indication><Indication id="230">Neoplasm</Indication><Indication id="276">Prostate tumor</Indication><Indication id="281">Psoriasis</Indication><Indication id="31">Asthma</Indication><Indication id="42">Bladder tumor</Indication><Indication id="4250">Metastatic renal cell carcinoma</Indication><Indication id="427">Uterine cervix tumor</Indication><Indication id="49">Breast tumor</Indication><Indication id="54">Carcinoma</Indication><Indication id="755">Lung tumor</Indication><Indication id="799">Ovary tumor</Indication><Indication id="94">Dermatitis</Indication></IndicationsSecondary><ActionsSecondary><Action id="12366">Inactivated bacterial vaccine</Action><Action id="12379">Therapeutic vaccine</Action><Action id="1291">Cytokine release modulator</Action><Action id="15184">Systemic antipsoriatic product</Action><Action id="1545">Anticancer</Action><Action id="1593">Antimicrobial</Action><Action id="1594">Antibacterial</Action><Action id="1596">Immunomodulator</Action><Action id="2942">Anxiolytic</Action><Action id="524">Adjuvant</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="1647">Natural product</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra><Ephmra><Code>N5C</Code><Name>TRANQUILLISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-30T10:24:02.000Z</LastModificationDate><ChangeDateLast>2019-07-01T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1051823" linkType="Company"&gt;Immodulon Therapeutics&lt;/ulink&gt;, under license from &lt;ulink linkID="22356" linkType="Company"&gt;Silence Therapeutics&lt;/ulink&gt;, is developing IMM-201 (SRL-172; SRP-299) a natural bacterial product and an environmental bacterium called M. vaccae NCTC11659,  as a booster vaccine, for the potential  prevention of tuberculosis infection (TB). The company is also investigating IMM-201, for the potential treatment of post-traumatic stress disorder (PTSD). In December 2007, a phase II study had been initiated for TB  [&lt;ulink linkID="2074172" linkType="Reference"&gt;2074172&lt;/ulink&gt;]. In September 2016, development was ongoing [&lt;ulink linkID="1794703" linkType="Reference"&gt;1794703&lt;/ulink&gt;]. In September 2018, clinical development was ongoing for TB infection and preclinical development for PTSD [&lt;ulink linkID="2074201" linkType="Reference"&gt;2074201&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;SRL-172, a heat-killed suspension of Mycobacterium vaccae, was under development previously by SR Pharma for the potential treatment of cancer and infectious diseases [&lt;ulink linkID="196495" linkType="reference"&gt;196495&lt;/ulink&gt;], [&lt;ulink linkID="312958" linkType="reference"&gt;312958&lt;/ulink&gt;]. In November 1997, SRL-172 failed a phase III TB trial [&lt;ulink linkID="312958" linkType="reference"&gt;312958&lt;/ulink&gt;] and in April 2001, disappointing phase III trial results for non-small cell lung cancer (NSCLC) were disclosed [&lt;ulink linkID="416039" linkType="reference"&gt;416039&lt;/ulink&gt;]. In January 2003, development was ongoing both as a monotherapy and as a vaccine adjuvant in the treatment of cancer and infectious diseases [&lt;ulink linkID="475635" linkType="reference"&gt;475635&lt;/ulink&gt;]; however, by March 2003, it was in development only as a vaccine adjuvant [&lt;ulink linkID="480847" linkType="reference"&gt;480847&lt;/ulink&gt;]. In April 2003, there were 2 main ongoing studies of SRL-172. The first an Australian phase I study in chronic hepatitis, final results of which were expected during the second half of 2003. The second was a five-year NIH-funded investigator-led 2000-patient TB-prevention study in HIV-positive patients in Tanzania that had commenced in September 2001 [&lt;ulink linkID="484552" linkType="reference"&gt;484552&lt;/ulink&gt;]. In May 2003, SR Pharm confirmed that it had effectively discontinued development of SRL-172 in order to concentrate on &lt;ulink linkID="40449" linkType="Drug"&gt;SRP-299&lt;/ulink&gt;, a new Mycobacterium vaccae suspension formulation developed specifically for allergic disorders [&lt;ulink linkID="488463" linkType="reference"&gt;488463&lt;/ulink&gt;], [&lt;ulink linkID="456820" linkType="reference"&gt;456820&lt;/ulink&gt;]. In May 2003, SRL-172 was continuing to be investigated as a potential adjuvant in investigator-led cancer studies and SR Pharma was still seeking to outlicense the drug for this indication [&lt;ulink linkID="488463" linkType="reference"&gt;488463&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2001, following disappointing phase III trial results for NSCLC, a review of the SRL-172 cancer program was initiated [&lt;ulink linkID="416039" linkType="reference"&gt;416039&lt;/ulink&gt;], [&lt;ulink linkID="416042" linkType="reference"&gt;416042&lt;/ulink&gt;]. By March 2002, the review had concluded that the results produced to date supported the further development of SRL-172 as a cancer therapeutic, particularly in combination with other biological products such as IL-2 in renal cancer and in late-stage disease. However, SR Pharma commented that it would need to seek funding through an out-licensing agreement for SRL-172 before further phase III cancer trials could be undertaken [&lt;ulink linkID="456819" linkType="reference"&gt;456819&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In September 2010, the European Commission (EC) granted Orphan Drug Designation for IMM-201 for the treatment of tuberculosis [&lt;ulink linkID="2073653" linkType="Reference"&gt;2073653&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Lung cancer&lt;/subtitle&gt;In October 1998, a 400-patient, randomized phase III trial (SR-ON-12) in NSCLC commenced in 30 centers across Europe, including sites in the UK, Austria, Germany, Poland and Hungary. The trial was expected to last for 2.5 years, with interim results expected in January 2000 [&lt;ulink linkID="312986" linkType="reference"&gt;312986&lt;/ulink&gt;], [&lt;ulink linkID="313394" linkType="reference"&gt;313394&lt;/ulink&gt;]. Recruitment of 400 patients to the pan-European trial was completed in September 1999, 3 months ahead of schedule [&lt;ulink linkID="369537" linkType="reference"&gt;369537&lt;/ulink&gt;], [&lt;ulink linkID="406245" linkType="reference"&gt;406245&lt;/ulink&gt;]; in March 2000, results were expected in early 2001 [&lt;ulink linkID="371076" linkType="reference"&gt;371076&lt;/ulink&gt;]. As of September 2000, SR Pharma was in discussions with potential US marketing partners, with the aim of submitting product approval applications in 2001 [&lt;ulink linkID="405931" linkType="reference"&gt;405931&lt;/ulink&gt;]. In April 2001, slightly later than anticipated [&lt;ulink linkID="416037" linkType="reference"&gt;416037&lt;/ulink&gt;], results from this phase III trial were announced. A total of 418 patients were treated with either standard chemotherapy or standard chemotherapy combined with SRL-172; however, it was shown that there was no significant difference between the two groups in terms of overall survival. There was a trend towards a benefit at week 15 (p = 0.061). A review of the SRL-172 cancer program was initiated at this time, with the outcome expected to be presented at the AGM in June 2001 [&lt;ulink linkID="416039" linkType="reference"&gt;416039&lt;/ulink&gt;]. At the AGM, it was disclosed that the review was ongoing and was due to be concluded at a meeting of the company's cancer scientific advisory board in September 2001 [&lt;ulink linkID="416042" linkType="reference"&gt;416042&lt;/ulink&gt;]. In July 2001, further results from the trial were released showing improvements in the quality of life of 183 patients treated with SRL-172 in addition to standard anticancer drugs, compared with 177 patients receiving standard treatment alone. Global Health Status was significantly improved for SRL-172-treated patients both during the treatment phase and over the duration of the study [&lt;ulink linkID="416880" linkType="reference"&gt;416880&lt;/ulink&gt;]. Methodological problems, such as the reduced proportion of patients receiving maintenance SRL-172 therapy and the low response rate for quality of life questionnaires, limited the statistical significance of this trial [&lt;ulink linkID="457075" linkType="reference"&gt;457075&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2002, a multi-dose trial of SRL-172 in SCLC was underway. An interim analysis was expected in July 2002 [&lt;ulink linkID="457103" linkType="reference"&gt;457103&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A third phase II trial in 28 patients with asymptomatic NSCLC and mesothelioma was conducted; however, some of the patients not treated with SRL-172 eventually received it on compassionate grounds, so results were inconclusive [&lt;ulink linkID="456821" linkType="reference"&gt;456821&lt;/ulink&gt;], [&lt;ulink linkID="457075" linkType="reference"&gt;457075&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Interim results from a 28-patient, phase II, SCLC trial were disclosed by SR Pharma in July 1999. These showed that treatment with SRL-172, in addition to chemotherapy, resulted in a 61% survival benefit compared with chemotherapy alone, 13.8 months versus 8.5 months [&lt;ulink linkID="406249" linkType="reference"&gt;406249&lt;/ulink&gt;]. Final results from this study were published in March 2000, and revealed that treatment with SRL-172, supplementary to standard chemotherapy, resulted in a 49% increase in survival (12.9 months compared to 8.6 months for chemotherapy alone). Overall, the drug was well tolerated with a good safety profile [&lt;ulink linkID="369537" linkType="reference"&gt;369537&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 1999, SR Pharma disclosed the final results from its phase II trial in advanced NSCLC and mesothelioma. These results indicated that treatment with SRL-172, in combination with standard chemotherapy, extended median survival from 7.6 months to 9.8 months (29%), compared to treatment with chemotherapy alone. The proportion of patients alive after 1 year was 42% for SRL-172 and chemotherapy, versus 18% for chemotherapy alone In addition, this study showed SRL-172 to be well tolerated with a good safety profile [&lt;ulink linkID="406245" linkType="reference"&gt;406245&lt;/ulink&gt;], [&lt;ulink linkID="456821" linkType="reference"&gt;456821&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results of a phase II randomized trial (SR-ON-05) showed that in 84 lung cancer patients, those treated with chemotherapy plus SRL-172 had improved survival over those treated with chemotherapy alone [&lt;ulink linkID="278842" linkType="reference"&gt;278842&lt;/ulink&gt;], [&lt;ulink linkID="457075" linkType="reference"&gt;457075&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Renal cancer&lt;/subtitle&gt;In August 1998, Stanford Rook started treating patients in a phase II, 60-patient, UK trial in metastatic renal cell carcinoma [&lt;ulink linkID="312987" linkType="reference"&gt;312987&lt;/ulink&gt;], [&lt;ulink linkID="313394" linkType="reference"&gt;313394&lt;/ulink&gt;]. By mid-1999, patient recruitment in this multicenter trial was almost complete, with 57 out of 60 patients enrolled in the UK and also in France. Results from this renal cell cancer trial were scheduled to be reported in the first quarter of 2001 [&lt;ulink linkID="405931" linkType="reference"&gt;405931&lt;/ulink&gt;]; the trial was completed by June 2001 [&lt;ulink linkID="416042" linkType="reference"&gt;416042&lt;/ulink&gt;], and results were announced shortly thereafter. There was a significant improvement in survival benefit observed for patients treated with SRL-172, although the patient groups were not prospectively randomized. This population survived for 403 days, compared to 368 for patients on biological therapy and 218 for patients receiving chemotherapy (p = 0.038 for the whole group, and 0.001 comparing SRL-172 and chemotherapy only) [&lt;ulink linkID="416044" linkType="reference"&gt;416044&lt;/ulink&gt;], [&lt;ulink linkID="457075" linkType="reference"&gt;457075&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In February 2001, SR Pharma and YMB entered into an agreement to investigate SRL-172 in conjunction with IPS-21, YMB's proprietary cancer antigen. This collaboration was to include trials to investigate the feasibility of using an IPS-21/SRL-172 combination as a vaccine for the treatment of hormone-dependent cancers such as prostate cancer. Trials were to be funded by YMB and carried out by SR Pharma in the UK. The agreement gave YMB the right to an exclusive license to develop SRL-172 for use in combination with certain other cancer antigens [&lt;ulink linkID="397541" linkType="reference"&gt;397541&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase I/II trial SR-ON-03, ten patients with advanced hormone-refractory prostate cancer were treated at monthly intervals with SRL-172. Five patients experienced a reduction in PSA at some time during therapy [&lt;ulink linkID="457075" linkType="reference"&gt;457075&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 1998, the licensee, Onyvax, was to evaluate SRL-172 in combination with its cell-based cancer vaccines (qv). Onyvax was to fund research; clinical trials were expected to begin in 1998 for prostate cancer [&lt;ulink linkID="283022" linkType="reference"&gt;283022&lt;/ulink&gt;]. The phase I/II trial in 60 patients demonstrated that the combination was well-tolerated and induced significant antibody and cellular responses [&lt;ulink linkID="457075" linkType="reference"&gt;457075&lt;/ulink&gt;]. The deal also gave Onyvax options to an exclusive license to develop cancer vaccines incorporating SRL-172 [&lt;ulink linkID="282905" linkType="reference"&gt;282905&lt;/ulink&gt;]. By May 2002, Onyvax was no longer involved in the development of SRL-172 [&lt;ulink linkID="450895" linkType="reference"&gt;450895&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Melanoma and other cancers&lt;/subtitle&gt;In October 1999, results from an open-label phase II trial of SRL-172 in melanoma demonstrated that approximately 25% of patients had a beneficial clinical response to the drug. In a significant number of patients, the positive immune response induced by SRL-172 correlated with improved survival [&lt;ulink linkID="406074" linkType="reference"&gt;406074&lt;/ulink&gt;]. Trial SR-ON-02 enrolled 24 patients with stage IV malignant melanoma, who were treated at 2-week intervals for three doses, then monthly. IL-2 production from PBMCs was increased in 39% of patients and was associated with nearly doubled survival [&lt;ulink linkID="457075" linkType="reference"&gt;457075&lt;/ulink&gt;]. No further development has been reported for melanoma since that time.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Mycobacterium infections&lt;/subtitle&gt;By December 2007, a randomised phase II  trial was initiated in Tanzania in adolescents to evaluate the safety and efficacy of M. vaccae NCTC11659, as a booster TB vaccine  [&lt;ulink linkID="2074172" linkType="Reference"&gt;2074172&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2007, a phase I  trial was completed [&lt;ulink linkID="2074172" linkType="Reference"&gt;2074172&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2002, results from a comparison of chest X-rays collected during the previous three trials were expected by the second quarter of 2002. At this time, SR Pharma planned seeking approval for SRL-172 in combination with anti-TB therapeutics If these results were encouraging. The company had also applied to the NIH for funding for a trial of SRL-172 in multi-drug resistant TB. This trial was to start during 2002 if funds were raised [&lt;ulink linkID="456819" linkType="reference"&gt;456819&lt;/ulink&gt;]. However, no further development by SR Pharma was reported.&lt;/para&gt;&lt;para&gt;In September 2001, a five-year NIH-funded investigator-led 2000-patient TB-prevention study in HIV-positive patients in Tanzania commenced [&lt;ulink linkID="456819" linkType="reference"&gt;456819&lt;/ulink&gt;]. This was ongoing in April 2003 [&lt;ulink linkID="484552" linkType="reference"&gt;484552&lt;/ulink&gt;]. By March 2014,   the 7-year, double-blind, randomized, controlled DarDar Trial, conducted by &lt;ulink linkID="30837" linkType="Company"&gt;Dartmouth-Hitchcock Medical Center&lt;/ulink&gt; and  Dartmouth's &lt;ulink linkID="1072700" linkType="Company"&gt;Geisel School of Medicine&lt;/ulink&gt;, demonstrated that the vaccine was safe and 39% effective in the prevention of TB in HIV-infected adults with a CD4 cell count of at least 200 cells/ml [&lt;ulink linkID="1536532" linkType="Reference"&gt;1536532&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 1997, SRL-172 failed a pivotal, phase III, 347-patient, South African TB trial [&lt;ulink linkID="312958" linkType="reference"&gt;312958&lt;/ulink&gt;]. The company had previously announced it would not be funding any further TB trials itself [&lt;ulink linkID="265772" linkType="reference"&gt;265772&lt;/ulink&gt;]. Two trials in Malawi and Zambia were proceeding, however, funded by the UK government; results were expected in late 1999 [&lt;ulink linkID="313394" linkType="reference"&gt;313394&lt;/ulink&gt;]. The results were reported in April 2001. Out of 112 HIV negative TB patients, 88 (78.6%) were culture negative after 8 weeks treatment with SRL-172, compared to 77 of 116 (66.4%) receiving placebo. Similar results were obtained in a phase I/II trial in Uganda [&lt;ulink linkID="416038" linkType="reference"&gt;416038&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1997, a phase II/III trial was initiated at the East London TB center in the UK. It was thought that, unlike conventional chemotherapy which targets replicating tubercle bacilli, SRL-172 acts on dormant, or near dormant bacilli [&lt;ulink linkID="196495" linkType="reference"&gt;196495&lt;/ulink&gt;], [&lt;ulink linkID="248354" linkType="reference"&gt;248354&lt;/ulink&gt;]. However, the company's efforts to develop the compound in the treatment of TB were suspended at the beginning of 1998, subsequent to the failure of the South African TB trial [&lt;ulink linkID="313394" linkType="reference"&gt;313394&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By 1995, in phase II studies in Gambia and Vietnam, SRL-172 administration with conventional chemotherapy improved the cure rate from 78% to 89%, with mortality being reduced from 8% to 3%. Studies in Romania and Kuwait had also been performed in patient populations receiving good quality chemotherapy. In this group, no statistical differences between placebo- and SRL-172-treated groups were noted, though resolution of some markers of TB were reported. Benefits were also demonstrated in a study in Nigeria in patients receiving low quality chemotherapy, though civil war impeded follow up evaluations [&lt;ulink linkID="196495" linkType="reference"&gt;196495&lt;/ulink&gt;]. By this time, the &lt;ulink linkID="20518" linkType="Company"&gt;National Institutes of Health&lt;/ulink&gt; was also to fund a phase I/II trial in HIV-negative patients in Uganda in collaboration with the &lt;ulink linkID="20553" linkType="Company"&gt;Case Western Reserve University&lt;/ulink&gt; [&lt;ulink linkID="196495" linkType="reference"&gt;196495&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II trial was also underway in 1996 to evaluate the potential of SRL-172 to prevent AIDS-related Mycobacterium avium infection [&lt;ulink linkID="220967" linkType="reference"&gt;220967&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hepatitis B virus infection&lt;/subtitle&gt;As of March 2002, a phase I study was underway in 50 chronic hepatitis B patients in Australia. Preliminary results were originally expected during 2002 [&lt;ulink linkID="456819" linkType="reference"&gt;456819&lt;/ulink&gt;], but this was later revised to the second half of 2003 [&lt;ulink linkID="484552" linkType="reference"&gt;484552&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2001, SR Pharma announced the start of two Australian trials of SRL-172, in combination with a hepatitis B virus (HBV) vaccine, for the prevention and treatment of HBV infection. The trials were to enroll chronically HBV-infected patients and patients who had been vaccinated but failed to produce adequate protective antibodies [&lt;ulink linkID="416040" linkType="reference"&gt;416040&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Allergy&lt;/subtitle&gt;By March 2001, a randomized, double-blind, placebo-controlled phase II trial of 41 children with moderate-to-severe atopic dermatitis demonstrated that a single intradermal injection of SRL-172 or placebo showed a mean 48% reduction in surface area affected by dermatitis compared with a mean of 4% reduction for the placebo group and a median 68% reduction in dermatitis severity score compared with 18% for the placebo group, at 3 months post-treatment. SRL-172 was generally well tolerated. By this time, the company was planning further trials using &lt;ulink linkID="40449" linkType="Drug"&gt;SRP-299&lt;/ulink&gt;, rather than SRL-172, specifically for the treatment of allergic disorders [&lt;ulink linkID="403054" linkType="reference"&gt;403054&lt;/ulink&gt;], [&lt;ulink linkID="456859" linkType="reference"&gt;456859&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 1999, results of a 24-patient, placebo-controlled phase I/II trial were released, demonstrating that a single dose of SRL-172 significantly improved the average late-phase airway response to allergen challenge relative to the pretreatment level. In contrast, the average late-phase airway response of placebo-treated patients showed no improvement. Treatment with SRL-172 also resulted in a positive immunological response, as demonstrated by beneficial changes in IL-5 and IgE antibody levels [&lt;ulink linkID="406074" linkType="reference"&gt;406074&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In 1998, an ongoing phase I/II trial involving 40 patients with hayfever, with or without asthma, showed that SRL-172 had beneficial effects mainly in patients with asthma [&lt;ulink linkID="278842" linkType="reference"&gt;278842&lt;/ulink&gt;]. This trial was expected to be completed by the end of 1999, with preliminary results expected during the second quarter [&lt;ulink linkID="313394" linkType="reference"&gt;313394&lt;/ulink&gt;]. In the patients with asthmatic symptoms associated with seasonal allergic rhinitis, those treated with SRL-172 experienced less symptoms and used significantly less bronchodilator medication [&lt;ulink linkID="456820" linkType="reference"&gt;456820&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2018, preclinical development in laboratory models of mental health disorders was ongoing  [&lt;ulink linkID="2074201" linkType="Reference"&gt;2074201&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, preclinical data were reported.  Mice injected with M. vaccae were more resilient to stress, showed less fear and anxiety in stressful situations. Treatment   changed serotonin activity in the brain, with similar beneficial effects to antidepressants or long-term exercise. Immunised mice were protected against colon inflammation which was caused or worsened by stress in unimmunised mice  [&lt;ulink linkID="2074201" linkType="Reference"&gt;2074201&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 1999, an agreement between SR Pharma and &lt;ulink linkID="27801" linkType="Company"&gt;Sakai Chemical Industry Co Ltd&lt;/ulink&gt; gave Sakai exclusive development and marketing rights for SRL-172 for the treatment of allergic disorders in Japan. The company also acquired an option to negotiate a licence for the rights to SRL-172 for the treatment of cancer in Japan. SR Pharma was to receive a $2 million license fee, milestone payments and royalties. This program included a UK-based phase II asthma trial [&lt;ulink linkID="369501" linkType="reference"&gt;369501&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 1998, Corixa and SR Pharma signed an agreement granting Corixa a license for SR Pharma's patent on Mycobacterium vaccae. The agreement covered the treatment of psoriasis, MS and RA. After preliminary tests investigating SRL-172 as a potential treatment for psoriasis, Stanford Rook had decided against pursuing this indication; however, after reviewing data from Corixa's Philippines trial of &lt;ulink linkID="24322" linkType="Drug"&gt;DDMV&lt;/ulink&gt;  the company stated that it believed progression of SRL-172 into the clinic for this indication was valid [&lt;ulink linkID="312958" linkType="reference"&gt;312958&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 1996, Stanford was seeking licensing partners for the development and marketing of SRL-172 [&lt;ulink linkID="220967" linkType="reference"&gt;220967&lt;/ulink&gt;]. In March 1999, the company entered a research collaboration with &lt;ulink linkID="25513" linkType="Company"&gt;Genesis Research and Development Corp Ltd&lt;/ulink&gt; of New Zealand, which covered asthma, tuberculosis and leprosy [&lt;ulink linkID="319110" linkType="reference"&gt;319110&lt;/ulink&gt;], [&lt;ulink linkID="406319" linkType="reference"&gt;406319&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Editor's note: Since the submission of this evaluation, the development of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; was confirmed as having been discontinued.&lt;/para&gt;&lt;para&gt;Keith Dredge, Division of Oncology, Department of Cellular &amp;amp; Molecular Medicine, St George's Hospital Medical School, Cranmer Terrace, London, SW17 0RE, UK&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Submission Date: 14 February 2003&lt;/subtitle&gt;Publication Date: 05 May 2003&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; is a heat-killed suspension of Mycobacterium vaccae, a rapidly growing environmental saprophyte from the same family as Mycobacterium tuberculosis. M vaccae, however, has immunotherapeutic properties against tuberculosis [&lt;ulink linkType="reference" linkID="267001"&gt;267001&lt;/ulink&gt;]. The enhancement of the immune response by &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; increases T-helper 1 (Th1) responses, which is also thought to be beneficial in conditions such as cancer, allergies, viral infections, asthma, hayfever, dermatitis and psoriasis [&lt;ulink linkType="reference" linkID="312958"&gt;312958&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="403054"&gt;403054&lt;/ulink&gt;]. &lt;ulink linkType="Company" linkID="22356"&gt;SR Pharma plc&lt;/ulink&gt; is currently investigating &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; as both a monotherapy and as a vaccine adjuvant in such conditions.&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; and related M vaccae-based technologies direct their actions against the body's immune response, and in particular, the activation of lymphocytes. This involves two alternative patterns of immune activity, designated Th1 and T-helper 2 (Th2). Although both Th1 and Th2 cells are essential for good health, there is growing evidence linking an imbalance of activity to a variety of diseases. A Th1 response is considered desirable for combating many intracellular infections and malignancies, while dominant Th2 activity has been associated with an increased incidence of allergic disorders such as asthma. &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; has the ability to induce Th1 responses and/or inhibit Th2 activity [&lt;ulink linkType="reference" linkID="484174"&gt;484174&lt;/ulink&gt;]. It also expresses heat-shock proteins that are thought to be involved in the presentation of tumor antigens as well as being targets for antitumor cytotoxic T-cell responses [&lt;ulink linkType="reference" linkID="419814"&gt;419814&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="463216"&gt;463216&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The adjuvant properties of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; have been demonstrated in prostate cancer models using autologous and allogeneic vaccines [&lt;ulink linkType="reference" linkID="483389"&gt;483389&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="483390"&gt;483390&lt;/ulink&gt;]. In patients with hormone-refractory cancer, failure to switch from a Th2 to a Th1 cytokine profile in response to vaccination with &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; may be associated with poor prognosis [&lt;ulink linkType="reference" linkID="483390"&gt;483390&lt;/ulink&gt;]. The importance of Th1 cytokine induction by &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; is further suggested by immunization of mice, which resulted in strong type 1 immune responses characterized by immunoglobulin G2a (IgG2a) antibodies and IFNgamma production [&lt;ulink linkType="reference" linkID="483391"&gt;483391&lt;/ulink&gt;]. Suppression of pre-existing Th2 responses [&lt;ulink linkType="reference" linkID="377318"&gt;377318&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="476974"&gt;476974&lt;/ulink&gt;] and evidence of suppression of Th2 type cytokines such as IL-4 [&lt;ulink linkType="reference" linkID="454815"&gt;454815&lt;/ulink&gt;] have also been documented. Cells of the innate immune system, such as natural killer cells, are activated in patients with malignant mesothelioma [&lt;ulink linkType="reference" linkID="454815"&gt;454815&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Founded in 1992, SR Pharma are developing M vaccae-based technology to develop other products such as &lt;ulink linkType="Drug" linkID="40449"&gt;SRP-299&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="22356"&gt;SR Pharma plc&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="27801"&gt;Sakai Chemical Industry Co Ltd&lt;/ulink&gt;) and AVAC, which is in clinical development for asthma and atopic dermatitis in a joint venture with &lt;ulink linkType="Company" linkID="25513"&gt;Genesis Research and Development Corp Ltd&lt;/ulink&gt;. Additionally, Corixa Corporation, &lt;ulink linkType="Company" linkID="21022"&gt;Zenyaku Kogyo Co Ltd&lt;/ulink&gt; and Genesis are developing &lt;ulink linkType="Drug" linkID="24322"&gt;PVAC&lt;/ulink&gt;, a proprietary product derived from the technology, as a treatment for psoriasis under licence from SR Pharma. &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; has been well tolerated in extensive clinical trials and ongoing clinical experience with &lt;ulink linkType="Drug" linkID="40449"&gt;SRP-299&lt;/ulink&gt;, AVAC and &lt;ulink linkType="Drug" linkID="24322"&gt;PVAC&lt;/ulink&gt; appears to demonstrate similarly favorable safety profiles.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;Professors John Stanford and Graham Rook formed the belief that resistance to tuberculosis and other infections was linked to exposure to microbes in the soil. Further research indicated that M vaccae could be the protective organism, and small studies with a suspension of a specifically selected and killed strain of M vaccae conducted in Africa, Europe, South America and the Middle East suggested potential activity in a number of diseases [&lt;ulink linkType="reference" linkID="486009"&gt;486009&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="486013"&gt;486013&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="486017"&gt;486017&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="486022"&gt;486022&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="486024"&gt;486024&lt;/ulink&gt;]. Mycobacterium species have been phylogenetically separated based on the rapid- and slow-growing strains; the majority of the slow-growing members of the genus represent the most recently evolved organisms. The various strains have been defined by the following taxa: (i) Mycobacterium neoaurum and M diernhoferi; (ii) M gadium; (iii) the M chubuense cluster; (iv) the M fortuitum cluster; (v) M kommossense; (vi) M sphagni; (vii) M fallax and M chitae; (viii) M aurum and M vaccae; (ix) the M flavescens cluster; and, (x) M chelonae subsp abscessus [&lt;ulink linkType="reference" linkID="483392"&gt;483392&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In an attempt to isolate active components of M vaccae, a number of high molecular weight (MW) proteoglycans with considerable immunological and antineoplastic activity have been identified. The structure of one of these, PS4A, obtained by extraction with boiling water, seems to consist of a basic unit with a 20-kDa protein core to which are attached glucans and O-methylated 4-kDa polysaccharides. The MW is ~ 50 kDa, but because of self-association, that of the recovered high MW fraction is &amp;gt; 150 kDa. A similar, but even larger, molecule (PS4alpha: MW of ~ 20 MDa) is obtained by cold extraction with urea. Both are active in vivo against an S-180 murine sarcoma model but have no in vitro activity, suggesting an antitumor effect involving activated macrophages [&lt;ulink linkType="reference" linkID="483393"&gt;483393&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="483394"&gt;483394&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;M vaccae is an alternative mycobacterial cloning host that has been largely overlooked. It has recently been suggested, however, that M vaccae is an additional cloning host that may be useful for certain aspects of mycobacterial biology and may provide flexibility [&lt;ulink linkType="reference" linkID="483395"&gt;483395&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;Intraperitoneal administration of M vaccae resulted in poor proliferation of M vaccae-primed T cells when the antigen was presented by peritoneal cells. This non-responder state of mice to M vaccae by intraperitoneal administration could be corrected by prior treatment with poly I:poly C, an interferon inducer or indomethacin, a prostaglandin inhibitor. The authors concluded that the failure of mice to respond to M vaccae by intraperitoneal immunization is the result of the poor efficiency of presentation of M vaccae antigen [&lt;ulink linkType="reference" linkID="483396"&gt;483396&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="484177"&gt;484177&lt;/ulink&gt;]. Routine administration of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; to humans is usually via the intradermal route [&lt;ulink linkType="reference" linkID="459427"&gt;459427&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="483397"&gt;483397&lt;/ulink&gt;]. It is of interest to note, however, that oral administration of M vaccae has an effect on the immune response. Mice given M vaccae in their drinking water for 3 weeks immediately, 27, or 54 days before they were injected subcutaneously with BCG resulted in enhancement, masking or interference of the BCG-induced response, suggesting that the results of BCG vaccination for a particular human population could be influenced by oral exposure to indigenous mycobacteria [&lt;ulink linkType="reference" linkID="483398"&gt;483398&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Some studies have focused on suitable delivery vehicles for immunostimulants or the expression of peptides in &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt;. For example, chitosan nanoparticles, readily prepared without the use of organic solvents, are a suitable vehicle for the delivery of immunostimulants from M vaccae and such formulations have potential as antitumor agents [&lt;ulink linkType="reference" linkID="483393"&gt;483393&lt;/ulink&gt;]. Moreover, a novel epitope delivery system based on the insertion of peptides within a permissive loop of a bacterial superoxide dismutase molecule allowed high-level expression of heterologous peptides in M vaccae [&lt;ulink linkType="reference" linkID="483399"&gt;483399&lt;/ulink&gt;].&lt;br/&gt; &lt;br/&gt;Animal models have revealed &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; to be a useful compound for a number of disease states and, in particular, as an adjuvant for those vaccines and immunotherapies where CD8+ cytotoxic T-lymphocyte (CTL) responses to exogenous proteins are important [&lt;ulink linkType="reference" linkID="463215"&gt;463215&lt;/ulink&gt;]. Immunization with M vaccae generates CD8+ CTLs that kill M tuberculosis-infected macrophages. Enhanced IFNgamma and interleukin (IL)-12 was also observed in cocultures of CD8+ T-cells and M tuberculosis-infected macrophages [&lt;ulink linkType="reference" linkID="463216"&gt;463216&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; suppresses airway eosinophilia by inducing allergen-specific regulatory T cells [&lt;ulink linkType="reference" linkID="456831"&gt;456831&lt;/ulink&gt;]. Reduction of antigen-induced airway hyperreactivity and increasing numbers of eosinophils in a mouse model of allergic pulmonary inflammation is independent of IFNgamma, induced long-term and antigen-specific protection, and, therefore, has both prophylactic and therapeutic potential for the treatment of allergic diseases [&lt;ulink linkType="reference" linkID="483400"&gt;483400&lt;/ulink&gt;]. This effectiveness in attenuating allergic airway inflammation was also shown using M vaccae via nasal administration but not intraperitoneal injection [&lt;ulink linkType="reference" linkID="483401"&gt;483401&lt;/ulink&gt;]. Furthermore, attenuating airway hyperresponsiveness to methacholine 24 h after an OVA challenge was prevented by M vaccae and was associated with increased plasma IL-12 levels and decreased IL-4 levels [&lt;ulink linkType="reference" linkID="483402"&gt;483402&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; is administered via the intradermal route to ensure efficient uptake by langerhans cells in the skin that act as antigen-presenting cells. It is widely believed that presentation of bacterial antigens in this fashion to T-cells stimulates the production of Th1-type cytokines. The immunoregulative mechanism of M vaccae has been investigated in mice. Immunohistochemistry and pathological slices were examined to investigate the correlation between the expression of IFNgamma, IL-4 and inducible nitric oxide synthase (iNOS), and tissue injury. Th1 cells predominated, and iNOS expression increased in the acute phase and decreased in the chronic phase. M vaccae enhanced the protective immunological response by inducing Th1 response and inhibiting Th2 response [&lt;ulink linkType="reference" linkID="484174"&gt;484174&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism &lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;The toxicity of intratumoral/intrapleural &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; was determined in addition to intradermal &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; and standard chemotherapy (mitomycin-C, vinblastine and cisplatin) in patients with malignant mesothelioma. &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; was safe when administered into tumor deposits and the pleural cavity into these patients [&lt;ulink linkType="reference" linkID="454815"&gt;454815&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; was administered intraperitoneally 3 weeks prior to chemotherapy and at doses from 1 microg to 1 mg bacilli. Patients (n = 16) also received 1 mg bacilli intradermally four-times weekly [&lt;ulink linkType="reference" linkID="454815"&gt;454815&lt;/ulink&gt;]. No dose-limiting toxicity (DLT) was observed but greater toxicity occurred at the highest dose. Six partial responses were observed [&lt;ulink linkType="reference" linkID="454815"&gt;454815&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I/II trial of patients (n = 24) with stage IV malignant melanoma, &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; had minimal toxicity with mild local inflammation at the site of injection. These injections were given at 15-day intervals for the first three injections, and then monthly. Patients demonstrating an IL-2 induction in peripheral blood leukocytes had increased survival [&lt;ulink linkType="reference" linkID="410537"&gt;410537&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Immunotherapy with M vaccae for chronic plaque psoriasis improved the psoriasis area severity index (PASI) in immunotherapy recipients [&lt;ulink linkType="reference" linkID="463213"&gt;463213&lt;/ulink&gt;]. Confirmation of this activity was demonstrated by another study that found that by 12 weeks, 14 of 24 patients (58%) had marked improvement in their PASI score (&gt; 50% reduction), two had moderate improvement (25 to 50% reduction), six were unchanged (&amp;lt; 25% reduction), and two had worsened (&gt; 5% increase). By 24 weeks, 11 of 22 patients continued to show &amp;gt; 50% improvement. Five patients had complete clearance of skin lesions that lasted for at least 6 months, indicating the tolerability and efficacy of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; in psoriasis patients [&lt;ulink linkType="reference" linkID="463214"&gt;463214&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The effects of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; have also been established on cell-mediated immunity of patients with pulmonary tuberculosis. Improvement of clinical symptoms, resolution of pulmonary lesions, negative conversion of sputum and changes of immunological functions have been observed, suggesting that &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; is a good immunotherapy preparation that promotes sputum-negative conversion and activation of cell-mediated immunity [&lt;ulink linkType="reference" linkID="484175"&gt;484175&lt;/ulink&gt;]. A recent Cochrane review, however, concluded that M vaccae does not benefit patients with tuberculosis [&lt;ulink linkType="reference" linkID="483403"&gt;483403&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I/II trial, patients (n = 10) with advanced hormone-refractory prostate cancer were given &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; at monthly intervals. Half the patients had a reduction in their prostate-specific antigen levels during therapy [&lt;ulink linkType="reference" linkID="457075"&gt;457075&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A randomized phase II trial of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; with or without low-dose IL-2 as a treatment for stage IV malignant melanoma found that 19% of patients (n = 16) in the &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt;/IL-2 arm had partial remission with minimal toxicity [&lt;ulink linkType="reference" linkID="484191"&gt;484191&lt;/ulink&gt;]. A phase II randomized trial in renal cancer patients suggested survival benefits in comparison with those receiving chemotherapy alone [&lt;ulink linkType="reference" linkID="416044"&gt;416044&lt;/ulink&gt;]. This trial enrolled 60 patients and compared &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt;-treated patients with historical controls. Mean survival for chemotherapy alone was 218 days, while &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt;-treated patients survived for an average of 403 days [&lt;ulink linkType="reference" linkID="416044"&gt;416044&lt;/ulink&gt;]. This was a statistically significant difference. Further evidence for improved overall survival in comparison with chemotherapy has recently been observed in 60 patients with metastatic renal cell carcinoma [&lt;ulink linkType="reference" linkID="484190"&gt;484190&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A series of randomized studies to test the feasibility and toxicity of combining a preparation of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; with a multidrug chemotherapy regimen to treat patients with inoperable non-small-cell lung cancer (NSCLC) and mesothelioma were instigated. The authors concluded that there may be a beneficial interaction when chemotherapy is administered in combination with &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="454837"&gt;454837&lt;/ulink&gt;]. Patients (n = 28) with previously untreated NSCLC and mesothelioma received either chemotherapy alone or chemotherapy plus monthly intradermal injections of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="454837"&gt;454837&lt;/ulink&gt;]. Patients who received both chemotherapy and &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; had an improved response rate of 54% compared with 33% in the chemotherapy-alone group. Median survival was also higher in the combined group (9.7 versus 7.5 months) and 42 versus 18% at one year [&lt;ulink linkType="reference" linkID="454837"&gt;454837&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II study to test the clinical activity, feasibility and safety of combining &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; with chemotherapy to treat patients with small-cell lung cancer (SCLC) (n = 28) found a trend to improved median survival in SCLC with the combination of chemotherapy and &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; and no increased toxicity irrespective of drug regimen [&lt;ulink linkType="reference" linkID="476971"&gt;476971&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; was administered intradermally on day 0, weeks 4 and 8 and then every 3 to 6 months. After 12 to 15 weeks, the toxicity of chemotherapy was similar in both regimens [&lt;ulink linkType="reference" linkID="476971"&gt;476971&lt;/ulink&gt;]. A 61% survival benefit was observed in the drug-plus-chemotherapy group over the chemotherapy-alone group; 13.8 versus 8.5 months, respectively [&lt;ulink linkType="reference" linkID="406074"&gt;406074&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="406249"&gt;406249&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Lung cancer patients (n = 84) treated with &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; and chemotherapy had improved survival compared with patients treated with chemotherapy alone [&lt;ulink linkType="reference" linkID="457075"&gt;457075&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; is also efficacious in children living in close contact with leprosy, affording 52.5 and 80.5% protection in the first four and eight years, respectively [&lt;ulink linkType="reference" linkID="483404"&gt;483404&lt;/ulink&gt;]. Children aged five to 18 years (n = 41) with moderate-to-severe atopic dermatitis treated with an intradermal injection of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; in a randomized, placebo-controlled, double-blind trial demonstrated a mean 48% reduction in surface area affected by dermatitis compared with a mean 4% reduction for the placebo group at 3 months after injection, indicating a possible use in skin disorders [&lt;ulink linkType="reference" linkID="403054"&gt;403054&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="454831"&gt;454831&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In 2001, a multi-center trial in Europe enrolled patients (n = 418) with NSCLC; patients were randomized to receive either standard chemotherapy alone or chemotherapy combined with &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt;. Results did not demonstrate any difference in overall survival between those patients receiving standard chemotherapy and those additionally receiving &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt;, although there was a trend in favor of the combined treatment group during the 15-week treatment phase (p = 0.061) [&lt;ulink linkType="reference" linkID="416039"&gt;416039&lt;/ulink&gt;]. However, half the patients did not receive the full course of vaccine, and of those that did, half received &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; subcutaneously as opposed to the intradermal route, which has implications for the metabolism and hence the efficacy of the drug [A Dalgleish, personal communication]. In March 2002, SR Pharma suggested that &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; improved the quality of life in phase III lung cancer trials [&lt;ulink linkType="reference" linkID="456819"&gt;456819&lt;/ulink&gt;]. Global Health Status was improved significantly in patients taking &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt;, both during the treatment phase and during the entire study [&lt;ulink linkType="reference" linkID="416880"&gt;416880&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;In a phase I trial, no DLT was observed with &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt;, although some toxicity was observed at the highest dose (1 mg bacilli) [&lt;ulink linkType="reference" linkID="454815"&gt;454815&lt;/ulink&gt;]. Most studies using &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; report minimal or no toxicity. For example, a randomized, placebo-controlled trial using &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis (n = 1229) demonstrated that the agent was safe and well tolerated, although no significant effect of the drug was observed [&lt;ulink linkType="reference" linkID="476975"&gt;476975&lt;/ulink&gt;]. Mild local inflammation is often observed, with one study finding that 20% of patients had pustules with subsequent discharge and crusting [&lt;ulink linkType="reference" linkID="410537"&gt;410537&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;The use of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; in an immunotherapeutic setting for antituberculosis treatment appears to be questionable. The efficacy observed in skin-related conditions such as leprosy and dermatitis suggests that &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; may be an effective treatment for such conditions. However, as &lt;ulink linkType="Drug" linkID="24322"&gt;PVAC&lt;/ulink&gt; has demonstrated improved efficacy in the treatment of psoriasis, and &lt;ulink linkType="Drug" linkID="40449"&gt;SRP-299&lt;/ulink&gt; and AVAC have been specifically developed as a novel treatment for allergic disorders and asthma, the enhanced efficacy of these M vaccae-related compounds may prevent the further of development &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; itself for such indications. Nonetheless, the use of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; as an immunoadjuvant in a clinical cancer setting may be more promising. The mild adverse effects of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; should prove to be advantageous for the continued development of the drug as an adjuvant in cancer therapy. The use of the drug as an immunoadjuvant has the potential to be effective but requires appropriate clinical trial design to determine its value. Critically, strict adherence to clinical trial protocols such as the route of administration and the establishment of other variables such as the number and timing of administrations may increase the adjuvantivity of &lt;ulink linkType="Drug" linkID="11115"&gt;SRL-172&lt;/ulink&gt; and in doing so, increase its clinical efficacy against certain cancers.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1051823">Immodulon Therapeutics Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1935">Post traumatic stress disorder</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="2074172" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1051823">Immodulon Therapeutics Ltd</Company><Country id="TZ">Tanzania</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="2074201" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2003-05-07T00:00:00.000Z</StatusDate><Source id="458474" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1998-03-01T00:00:00.000Z</StatusDate><Source id="313394" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate><Source id="488463" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="755">Lung tumor</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate><Source id="488463" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate><Source id="488463" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="755">Lung tumor</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate><Source id="488463" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1107">Allergic rhinitis</Indication><StatusDate>2003-05-07T00:00:00.000Z</StatusDate><Source id="458474" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2003-05-07T00:00:00.000Z</StatusDate><Source id="458474" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="205">Melanoma</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate><Source id="488463" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="755">Lung tumor</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate><Source id="488463" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25528">Onyvax Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate>2002-05-13T00:00:00.000Z</StatusDate><Source id="450895" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="54">Carcinoma</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate><Source id="488463" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="427">Uterine cervix tumor</Indication><StatusDate>2003-05-07T00:00:00.000Z</StatusDate><Source id="458474" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1998-03-01T00:00:00.000Z</StatusDate><Source id="313394" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1998-03-01T00:00:00.000Z</StatusDate><Source id="313394" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="755">Lung tumor</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate><Source id="488463" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2003-05-07T00:00:00.000Z</StatusDate><Source id="458474" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1998-03-01T00:00:00.000Z</StatusDate><Source id="313394" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate><Source id="488463" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="42">Bladder tumor</Indication><StatusDate>2003-05-07T00:00:00.000Z</StatusDate><Source id="458474" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1998-03-01T00:00:00.000Z</StatusDate><Source id="313394" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate><Source id="488463" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="218">Mycobacterium infection</Indication><StatusDate>2003-05-07T00:00:00.000Z</StatusDate><Source id="458474" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="94">Dermatitis</Indication><StatusDate>2002-07-19T00:00:00.000Z</StatusDate><Source id="458474" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="755">Lung tumor</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate><Source id="488463" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1998-03-01T00:00:00.000Z</StatusDate><Source id="313394" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24845">YM BioSciences Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="230">Neoplasm</Indication><StatusDate>2001-02-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27801">Sakai Chemical Industry Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>2001-02-01T00:00:00.000Z</StatusDate><Source id="369501" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24845">YM BioSciences Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2001-02-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2003-05-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1935">Post traumatic stress disorder</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="2074172" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="2074172" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="2074201" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="218">Mycobacterium infection</Indication><StatusDate>1996-10-18T00:00:00.000Z</StatusDate><Source id="220967" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2001-07-19T00:00:00.000Z</StatusDate><Source id="416040" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>1996-10-18T00:00:00.000Z</StatusDate><Source id="248354" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="42">Bladder tumor</Indication><StatusDate>1996-10-18T00:00:00.000Z</StatusDate><Source id="248354" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2001-04-20T00:00:00.000Z</StatusDate><Source id="405931" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="94">Dermatitis</Indication><StatusDate>2001-03-27T00:00:00.000Z</StatusDate><Source id="403054" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>1998-08-01T00:00:00.000Z</StatusDate><Source id="312987" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate>1998-10-01T00:00:00.000Z</StatusDate><Source id="312986" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate>1998-10-01T00:00:00.000Z</StatusDate><Source id="312986" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate>1998-10-01T00:00:00.000Z</StatusDate><Source id="312986" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="AT">Austria</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate>1998-10-01T00:00:00.000Z</StatusDate><Source id="312986" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>1999-02-01T00:00:00.000Z</StatusDate><Source id="312958" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate>1998-10-01T00:00:00.000Z</StatusDate><Source id="312986" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="ZM">Zambia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1997-10-13T00:00:00.000Z</StatusDate><Source id="265772" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1997-10-13T00:00:00.000Z</StatusDate><Source id="265772" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1107">Allergic rhinitis</Indication><StatusDate>1997-06-03T00:00:00.000Z</StatusDate><Source id="278842" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>1997-09-01T00:00:00.000Z</StatusDate><Source id="263661" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate>1996-10-18T00:00:00.000Z</StatusDate><Source id="248354" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="427">Uterine cervix tumor</Indication><StatusDate>1996-10-18T00:00:00.000Z</StatusDate><Source id="248354" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>1996-10-18T00:00:00.000Z</StatusDate><Source id="248354" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>1996-10-18T00:00:00.000Z</StatusDate><Source id="248354" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate>1996-10-18T00:00:00.000Z</StatusDate><Source id="248354" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1107">Allergic rhinitis</Indication><StatusDate>1997-06-03T00:00:00.000Z</StatusDate><Source id="245354" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1995-10-12T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1995-10-12T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="54">Carcinoma</Indication><StatusDate>1995-10-12T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="NG">Nigeria</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1995-10-12T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="GM">Gambia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1995-10-12T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1995-10-12T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="RO">Romania</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>1995-10-12T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25528">Onyvax Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>1998-03-01T00:00:00.000Z</StatusDate><Source id="283022" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22356">Silence Therapeutics plc</Company><Country id="TZ">Tanzania</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>2001-09-30T00:00:00.000Z</StatusDate><Source id="457103" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27801">Sakai Chemical Industry Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>1999-11-11T00:00:00.000Z</StatusDate><Source id="369501" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1051823">Immodulon Therapeutics Ltd</OwnerCompany><Country id="X5">Europe</Country><Indication id="221">Mycobacterium tuberculosis infection</Indication><AwardedIndication>Treatment of tuberculosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-09-20T00:00:00.000Z</MileStoneDate><Source id="2073653" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2126375" linkType="reference" linkID="2126375"&gt;2126375&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1051823">Immodulon Therapeutics Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16450">Gilead Sciences Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20607">University of London</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22356">Silence Therapeutics plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>6</CountTotal></Company><Company><Company id="25513">Genesis Research and Development Corp Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="25520">University of Colorado System</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="25528">Onyvax Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27801">Sakai Chemical Industry Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="12">Patent - Non-Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="125872" title="Onyvax to evaluate Stanford Rook's SRL-172 in combination with cell-based anticancer vaccines"/><Deal id="125898" title="Corixa to develop SR Pharma's Mycobacterium vaccae patent and SRL-172"/><Deal id="125902" title="YM BioSciences to investigate SR Pharma's SRL-172 in conjunction with IPS-21 cancer antigen"/><Deal id="125905" title="Sakai to develop SR Pharma's SRL-172 and SRP-299 in Japan"/><Deal id="125907" title="Genesis to research Stanford Rook's SRL-172 for asthma, tuberculosis and leprosy"/><Deal id="126870" title="SR Pharma to obtain IP rights to SRL-172 from UCL"/><Deal id="250307" title="University of Colorado Boulder to conduct preclinical research on Immodulon's IMM-201 for tuberculosis   "/></Deals><PatentFamilies><PatentFamily id="1932161" number="WO-00039301" title="Methods for using mycobacterium tuberculosis molecules as immunological adjuvants"/><PatentFamily id="2426980" number="WO-2014045023" title="Treatment of post-traumatic stress disorder with isolated &lt;i&gt;Mycobacterium&lt;/i&gt;"/><PatentFamily id="602149" number="WO-09526742" title="Immunotherapeutic agent and its use."/><PatentFamily id="991137" number="WO-00182939" title="Treatment of conditions of the central nervous system using mycobacteria"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Immodulon Therapeutics Ltd" id="1051823"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gilead Sciences Inc" id="16450"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of London" id="20607"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Silence Therapeutics plc" id="22356"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Onyvax Ltd" id="25528"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sakai Chemical Industry Co Ltd" id="27801"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>